SI-BONE Inc.

NASDAQ: SIBN · Real-Time Price · USD
13.66
-0.62 (-4.34%)
At close: Apr 30, 2025, 3:59 PM
13.65
-0.07%
After-hours: Apr 30, 2025, 04:22 PM EDT

Company Description

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally.

It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.

The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion.

It markets its products primarily with a direct sales force, as well as through distributors.

The company was incorporated in 2008 and is headquartered in Santa Clara, California.

SI-BONE Inc.
SI-BONE Inc. logo
Country United States
IPO Date Oct 17, 2018
Industry Medical - Devices
Sector Healthcare
Employees 349
CEO Laura A. Francis MBA

Contact Details

Address:
471 El Camino Real
Santa Clara, California
United States
Website https://si-bone.com

Stock Details

Ticker Symbol SIBN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001459839
CUSIP Number 825704109
ISIN Number US8257041090
Employer ID 26-2216351
SIC Code 3841

Key Executives

Name Position
Laura A. Francis MBA Chief Executive Officer & Director
Anshul Maheshwari Chief Financial Officer
Aimee Einstein Vice President of People & Culture
Anthony J. Recupero President of Commercial Operations
Jeffrey W. Dunn Executive Chairman
Joyce Goto Vice President & Corporate Controller
Michael A. Pisetsky J.D. Chief Business & Legal Affairs Officer, Secretary and General Counsel
Nikolas F. Kerr Senior Vice President of Product, Marketing & Business Development
Saqib Iqbal Director of FP&A and Investor Relations
Troy Wahlenmaier Senior Vice President of US Sales

Latest SEC Filings

Date Type Title
Apr 25, 2025 ARS Filing
Apr 25, 2025 DEFA14A Filing
Apr 25, 2025 DEF 14A Filing
Apr 18, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 17, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 04, 2025 4 Filing
Apr 04, 2025 4 Filing
Apr 04, 2025 4 Filing
Mar 24, 2025 3 Filing
Feb 25, 2025 S-8 Filing